CBAY - CymaBay Therapeutics GAAP EPS of -$0.32 misses by $0.03
2023-11-07 16:25:02 ET
More on CymaBay Therapeutics
- CymaBay: Positive Phase 3 Data And Competitive Advantage Established
- CymaBay Therapeutics: Shares Jump On Confirmatory Seladelpar Data - As Good As It Gets?
- CymaBay Therapeutics, Inc. (CBAY) Q2 2023 Earnings Call Transcript
- CymaBay Therapeutics Q3 2023 Earnings Preview
- FDA expands breakthrough status for CymaBay's seladelpar
For further details see:
CymaBay Therapeutics GAAP EPS of -$0.32 misses by $0.03